Fig. 8
From: A tumor microenvironment-based prognostic index for osteosarcoma
The relationship between TMEindex and efficacy of immunotherapy and drug sensitivity. A, E Kaplan–Meier curves depict the OS difference between TMEindex-high and TMEindex-low groups after anti-PD-L1 immunotherapy in the IMvigor210-BLCA (A, log-rank P < 0.0001) and IMvigor210-Kidney cancer (B, log-rank P = 0.09) cohorts. B, F Rate of clinical response (complete response [CR]/partial response [PR] and stable disease [SD]/progressive disease [PD]) to anti–PD-L1 immunotherapy in TMEindex-high and TMEindex-low groups in the IMvigor210-BLCA (B) and IMvigor210-Kidney cancer (F) cohorts. C, G TMEindex in groups with different anti–PD-L1 clinical response status in the IMvigor210-BLCA (C) and IMvigor210-Kidney cancer (G) cohorts. The red represents CR/PR patients and the blue represents SD/PD patients. D, H ROC curves showing the OS prediction efficiency of the TMEindex in the IMvigor210-BLCA (D) and IMvigor210-Kidney cancer (H) cohorts. I The correlation between TMEindex and drug sensitivity (IC50 value). Each column represents a drug. The height of the column represents the correlation coefficient. The red represents drugs sensitive in TMEindex-high group and the blue represents drugs sensitive in TMEindex-low group